# Divi’s Laboratories Shares Surge Following Strong Q2 Earnings Report Jefferies raises target price by 23% citing robust CDMO business and peptide pipeline. - **Source:** [Economic Times](https://brifing.si/source/37791137-c35a-4ffe-b6a9-fe103afc9e48) - **Published:** 2026-11-09 - **Topic:** [Finance](https://brifing.si/c/finance) - **Original article:** - **On Brifing:** https://brifing.si/s/ebfffc4d-86a3-4402-a69e-4e2ee3ddee9a ## Market Performance Surge Shares of Divi’s Laboratories climbed 5% following the release of their second-quarter fiscal year 2027 financial results. This positive market reaction reflects investor confidence after the company reported a significant 64% year-over-year surge in net profit. The firm reached a total net profit of Rs 1,127 crore for the quarter. ## Jefferies Price Target Upgrade Following the impressive earnings report, brokerage firm Jefferies revised its outlook on the stock. They increased the target price by 23%, setting a new benchmark at Rs 12,550 per share. This adjustment signals a strong endorsement of the company’s current growth trajectory and its ability to deliver consistent financial returns. ## CDMO Business Expansion The primary driver behind the optimistic analyst outlook is the robust expansion of the company’s Contract Development and Manufacturing Organization (CDMO) business. This segment remains a critical pillar for the firm, providing specialized manufacturing services to global pharmaceutical partners. The growth here is essential for maintaining long-term revenue stability and market competitiveness. ## Margin and Pipeline Strength Beyond revenue growth, the company demonstrated strong EBITDA margins, indicating efficient operational management during the quarter. Furthermore, the firm is benefiting from a solid GLP peptide pipeline. These specialized compounds are increasingly vital in modern pharmaceutical treatments, positioning the company well to capture future demand within the global healthcare sector. ## Financial Context of Growth The 64% profit surge highlights the company's ability to scale operations effectively while managing costs. By leveraging its existing infrastructure, the firm has successfully capitalized on market opportunities in the pharmaceutical manufacturing space. This financial performance provides a clear indicator of the company's operational health and its strategic focus on high-value. ## Strategic Market Positioning Divi’s Laboratories continues to solidify its position as a key player in the global pharmaceutical supply chain. By focusing on complex manufacturing processes and high-demand peptide products, the company differentiates itself from generic competitors. This strategic alignment with global healthcare needs supports the sustained investor interest observed in recent trading sessions. ## Investor Sentiment Analysis The market's reaction suggests that investors are prioritizing companies with clear growth catalysts and strong balance sheets. The combination of double-digit profit growth and positive analyst revisions creates a favorable environment for shareholders. Market participants are closely monitoring how these operational successes translate into long-term value creation for the company's stakeholders. ## Future Outlook Considerations Looking ahead, the sustainability of these margins and the successful commercialization of the peptide pipeline will be crucial. Investors should watch for further updates on capacity utilization and new contract wins within the CDMO division. These factors will determine if the current stock momentum can be maintained throughout the coming fiscal year. ## Sources covering this story - https://economictimes.indiatimes.com/markets/stocks/news/divis-laboratories-shares-gain-another-5-after-q2-results-heres-why-jefferies-raised-target-price-by-23/articleshow/135671615.cms — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._